Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120803 · ClinicalTrials.gov registry record · Phase 2
Esomeprazole and Radiation Induced Esophagitis
A Phase 2 study of Locally Advanced Lung Carcinoma and Radiation Esophagitis, sponsored by Rush University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06120803 is a Phase 2 study of Locally Advanced Lung Carcinoma and Radiation Esophagitis that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06120803, a Phase 2 study of Locally Advanced Lung Carcinoma and Radiation Esophagitis, is actively recruiting participants, sponsored by Rush University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Esomeprazole 40 mg
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06120803
The ClinicalTrials.gov registry entry for NCT06120803 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Locally Advanced Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Esomeprazole 40 mg is the first listed.
NCT06120803 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06120803 about?
NCT06120803 is a clinical study titled "Esomeprazole and Radiation Induced Esophagitis". Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT06120803?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-03-01. Estimated completion is 2028-06-30.
What conditions does trial NCT06120803 study?
This clinical trial studies the following conditions: Locally Advanced Lung Carcinoma, Radiation Esophagitis.
What interventions are being tested in trial NCT06120803?
The interventions under investigation include: Esomeprazole 40 mg (DRUG).
Who is sponsoring clinical trial NCT06120803?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06120803 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.